Additional file 1 of Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study

Additional file 1: Table S1. STROBE-MR checklist. Table S2. Phenotype descriptions and distributions. Table S3. Lipid-lowering drug classes, substances, and target genes. Table S4. Genetic variants that were used as instrumental variables for high-density lipoprotein cholesterol. Table S5. Genetic variants that were used as instrumental variables for low-density lipoprotein cholesterol. Table S6. Genetic variants that were used as instrumental variables for triglyceride. Table S7. Genetic variants that were used as instrumental variables for apolipoprotein A. Table S8. Genetic variants that were used as instrumental variables for apolipoprotein B. Table S9. Association of genetically proxied lipid traits with risk of IPF. Table S10. Heterogeneity and pleiotropy tests of instrument effects （lipid traits on IPF). Table S11. Characteristics of lipid-modifying genetics variants in target genes using primary effect. Table S12. Association of genetically proxied lipid-modifying drugs with risk of CHD. Table S13. Association of genetically proxied lipid-modifying drugs with risk of IPF using primary effect. Table S14. Statistical power estimates for drug-target MR analyses using primary effect. Table S15. Association of genetically proxied lipid-modifying drugs with risk of IPF using alternative effect. Table S16. Characteristics of lipid-modifying genetics variants in target genes using alternative effect. Table S17. Statistical power estimates for drug-target MR analyses using alternative effect. Table S18. Heterogeneity and pleiotropy tests of instrument effects (primary lipid-modifying effect). Table S19. Heterogeneity and pleiotropy tests of instrument effects (alternative lipid-modifying effect). Table S20. Association of genetic mimicry of lipid-modifying drugs with risk of IPF accounting for LD structure. Table S21. Association between gene expression in tissues of identified targets and IPF in the SMR analysis.